Original Article. Study of the cytotoxic/toxic potential of the novel anticancer selenodiazoloquinolone on fibroblast cells and 3D skin model

Interdisciplinary Toxicology

Volumn 9, Issue 3-4, 2016, Pages 106-112

  Jantová, Soňa ^a   Toposká, Dominika ^a,b   Janošková, Michaela ^a   Pánik, Miroslav ^a   Milata, Viktor ^a  

^a SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

Author keywords

cytotoxicity; EpiDerm viability; fibroblast BHNF 1 cells; quinolones; tissue morphology

Indexed keywords

7 ETHYL 9 ETHYL 6 OXO 6,9 DIHYDRO[1,2,5]SELENADIAZOLO[3,4 H]QUINOLINE 7 CARBOXYLATE; ANTINEOPLASTIC AGENT; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; CARBOXYLIC ACID DERIVATIVE; CYTOTOXIC AGENT; IMMUNOMODULATING AGENT;

A-549 CELL LINE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BHNF 1 CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FIBROBLAST; HELA CELL LINE; HL-60 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; KERATINOCYTE; MELANOMA CELL LINE; TISSUE STRUCTURE; ANIMAL CELL; APOPTOSIS; DRUG CYTOTOXICITY; FEMALE; HUMAN TISSUE; IMMUNOMODULATION; MOUSE; NEWBORN; NONHUMAN; RAW 264.7 CELL LINE; SKIN FIBROBLAST; THREE DIMENSIONAL IMAGING;

EID: 85020523897     PISSN: 13376853     EISSN: 13379569     Source Type: Journal    
DOI: 10.1515/intox-2016-0014     Document Type: Article

References (40)

1. Adams M, Mahringer A, Kunert O, Fricker G, Efferth T, Bauer R. (2007). Cytotoxicity and p-glycoprotein modulating effects of quinolones and indoloquinazolines from the Chinese herb Evodia rutaecarpa. Planta Med 73: 1554-1557.
2. Asoh K, Kohchi M, Hyoudoh I, Ohtsuka T, Masubuchi M, Kawasaki K, Ebiike H, Shiratori Y, Fukami T, Kondoh O, Tsukaguchi T, Ishii N, Aoki Y, Shimma N, Sakaitani M. (2009). Synthesis and structure-Activity relationships of novel benzofuran farnesyltransferase inhibitors. Bioorg Med Chem Lett 19: 1753-1757.
3. Azema J, Guidetti B, Dewelle J, Le Calve B, Mijatovic T, Korolyov A, Vaysse J, Malet-Martino M, Martino R, Kiss R. (2009). 7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: Synthesis and in vitro biological evaluation as potential antitumor agents. Bioorg Med Chem 17: 5396-5407.
4. Barbieriková Z, Bella M, Lietava J, Dvoranová D, Staško A, Fözik T, Milata V, Jantová S, Brezová V. (2011a). Spectroscopic characterization and photoinduced processes of 4-oxoquinoline derivatives. J Photochem Photobiol A: Chemistry 224: 123-134.
5. Barbierikova Z, Bella M, Kučerák J, Milata V, Jantová S, Dvoranová D, Veselá M, Staško A, Brezová V. (2011b). Photoinduced Superoxide Radical Anion and Singlet Oxygen Generation in the Presence of Novel Selenadiazoloquinolones (An EPR Study). Photochem Photobiol 87: 32-44.
6. Barbieriková Z, Bella, M, Sekeráková L, Lietava J, Bobeničová M, Dvoranová D, Milata V, Sádecká J, Mercheková D, Topolská D, Heizer T, Hudec R, Czimerová A, Jantová S, Brezová V. (2013). Spectroscopic characterization, photoinduced processes and cytotoxic properties of substituted N-ethyl selenadiazoloquinolones. J Phys Org Chem 26: 565-574.
7. Bella M, Milata V. (2014). Synthesis of 9-ethyl[1, 2, 5]selenadiazolo[3, 4-h]quinolones by the application of modifi ed Gould-Jacobs reaction to N-ethyl-2, 1, 3-benzoselenadiazol-4-Amine. Arcivoc (v), 181-198.
8. DalhoffA, (2005). Immunomodulatory activities of fluoroquinolones. Infection 33: 55-70.
9. DalhoffA, Shalit I. (2003). Immunomodulatory effects of quinolones. Lancet Infect. Dis. 3: 359-371.
10. Darque A, Dumetre A, Hutter S, Casano G, Robin M, Pannecouque C, Azas N. (2009). Synthesis and biological evaluation of new heterocyclic quinolinones as anti-parasite and anti-HIV drug candidates. Bioorg Med Chem Lett 19: 5962-5964.
11. Drlica K, Zhao X. (1997). DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61: 377-392.
12. Drygin D, Siddiqui-Jain A, OBrien S, Schwaebe M, Lin A, Bliesath J, Ho C, Proffitt C, Trent K, Whitten J, Lim J, Von HoffD, Anderes K, Rice W. (2009). Anticancer activity of CX-3543: A direct inhibitor of rRNA biogenesis. Cancer Res 69: 7653-7661.
13. Foroumadi A, Emami S, Rajabalian S, Badinloo M, Mohammadhosseini N, Shafi ee A. (2009). N-Substituted piperazinyl quinolones as potential cytotoxic agents: structure-Activity relationships study. Biomed Pharmacother 63: 216-220.
14. George S, Pili R. (2013). Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer. Curr Oncol Rep 15: 65-68.
15. Golub A, Yakovenko O, Bdzhola V, Sapelkin V, Zien P, Yarmoluk S. (2006). Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J Med Chem 49: 6443-6450.
16. Hadjeri M, Peiller E, Beney C, Deka N, Lawson M, Dumontet C, Boumendjel A, (2004). Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones. J Med Chem 47: 4964-4970.
17. Huang L, Hsieh M, Teng C, Lee K, Kuo S. (1998). Synthesis and antiplatelet activity of phenyl quinolones. Bioorg Med Chem 6: 1657-1662.
18. Chang Y, Yang J, Kuo S, Chung J. (2009). Induction of mitotic arrest and apoptosis by a novel synthetic quinolone analogue, CWC-8, via intrinsic and extrinsic apoptotic pathways in human osteogenic sarcoma U-2 OS cells. Anticancer Res 29: 3139-3148.
19. Chou L., Yang J, Huang L, Wu H, Lu C, Chiang J, Chen K, Kuo S, Chung J. (2009). The synthesized 2-(2-fluorophenyl)-6, 7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells. J Gastroenterol 44: 1055-1063.
20. Chung DT, Tsai CY, Chen SJ, Chang LW, King CHR, Hsu CH, Chiu KM, Tan HC, Chang YT, Hsu MC. (2010). Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrobiol Agents Chemother 54: 411-417.
21. Jantová S, Letašiová S, Koňariková K, Milata V, Brezová V. (2010). Effect of new synthetically prepared quinolone ethyl-1, 4-dihydro-8-nitro-4-oxoquinoline-3-carboxylate on human leukemia cell line HL-60 without/with presence of UVA irradiation. Acta Chimica Slovaca 3: 51-72.
22. Jantová S, Koňariková K, Letašiová S, Paulovičová E, Milata V, Brezová V. (2011). Photochemical and phototoxic properties of ethyl 1, 4-dihydro-8-nitro-4-oxoquinoline-3-carboxylate, a new quinolone derivative. J Photochem Photobiol B-Biology 102: 77-91.
23. Jantová S, Mrvová N, Hudec R, Sedlák J, Pánik M, Milata V. (2016a) Pro-Apoptotic effect of new quinolone 7-ethyl 9-ethyl-6-oxo-6, 9-dihydro[1, 2, 5] selenadiazolo[3, 4-h]quinoline-7-carboxylate on cervical cancer cell line HeLa alone/with UVA irradiation. Toxicol in Vitro 33: 35-44.
24. Jantová S, Paulovičová E, Paulovičová L, Topolská D, Pánik M, Milata V. (2016b) The effects of novel selenadiazoloquinolone derivative on cancer cell proliferation, apoptosis and immunomodulatory activities. Cell Biol Toxicol [Accepted in Press].
25. Khodursky A, Zechiedrich E, Cozzarelli N. (1995). Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Nat Acad Sci USA 92: 11801-11805.
26. Letašiová S, Jantová S, Čipák L, Múčková M. (2006). Berberine-Antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett 239: 254-262.
27. Medeiros B, Landau H, Morrow M, Lockerbie R, Pitts T, Eckhardt S. (2007). The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates signifi cant cytotoxic synergism against human leukemia cell lines. Leukemia 21(4): 739-46.
28. Meyer E, Schwab F, Gastmeier P, Ruden H, Heininger A. (2007). Antifungal use in intensive care units. J Antimicrobiol Chemother 60: 619-624.
29. Oriel J. (1989). Use of quinolones in chlamydial infection. Rev Infect Dis 11: S1273-S1276.
30. Riesbeck K. (2002). Immunomodulating activity of quinolones: review. J Chemother 14: 3-12.
31. Santos F, Abreu P, Castro H, Paixao I, Cirne-Santos C, Giongo V, Barbosa J, Simonetti B, Garrido V, Bou-Habib D, Silva D, Batalha P, Temerozo J, Souza T, Nogueira C, Cunha A, Rodrigues C, Ferreira V, de Souza M. (2009). Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives. Bioorg Med Chem 17: 5476-5481.
32. Sharma PC, Jain A, Jain S. (2009). Fluoroquinolone antibacterials: A review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm 66: 587-604.
33. Sheng Z, Cao X, Peng S, Wang C, Li Q, Wang Y, Liu M. (2008). Ofloxacin induces apoptosis in microencapsulated juvenile rabbit chondrocytes by caspase-8-dependent mitochondrial pathway. Toxicol Appl Pharmacol 226: 119-127.
34. Sokolova G, Kunichan AD, Lazareva YV. (2009). Levofloxacin (Tavanic) in complex therapy of tuberculosis. Antibiot Khimioter 54: 31-37.
35. Tawfi k AF, Shoeb HA, Bishop SJ, Al-Shammary FJ, Shbl AM. (1990). Influence of new quinolones on normal immune capabilities. J Chemother 2: 300-3005.
36. Vinayaka AC, Sadashiva MP, Wu X, Biryukov SS, Stoute JA, Rangappa KS, Gowda DC. (2014). Facile synthesis of antimalarial odiazoloquinolone on fi-broblasts and skin model 1, 2-disubstituted 4-quinolones from 1, 3-bisarylmonothio-1, 3-diketones. Org Biomol Chem 12: 8555-8561.
37. Xia Y, Yang Z, Xia P, Hackl T, Hamel E, Mauger A, Wu J, Lee K. (2001). Antitumoragents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents. J Med Chem 44: 3932-3936.
38. Xiao ZP, Li HQ, Shi L, Lv PC, Song ZC, Zhu HL. (2008). Synthesis, antiproliferative activity, and structure-Activity relationships of 3-Aryl-1H-quinolin-4-ones. Chem Med Chem 3: 1077-1082.
39. Yamashita Y, Ashizawa T, Morimoto M, Hosomi J, Nakano H. (1992). Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res 52: 2818-2822.
40. You Q, Li Z, Huang C, Yang Q, Wang X, Guo Q, Chen X, He X, Li T, Chern J. (2009). Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by Scaffold modifi cation. J Med Chem 52: 5649-5661.